Choline

Choline is not merely a supplement—it is an essential nutrient with an official Adequate Intake (AI) set by the Institute of Medicine. Yet approximately 90% of Americans fail to meet the recommended intake of 425 mg/day for women and 550 mg/day for men. This widespread deficiency has real consequences: choline is required for acetylcholine synthesis, phosphatidylcholine production, betaine-mediated homocysteine reduction, and very-low-density lipoprotein (VLDL) assembly in the liver. Without adequate choline, fat accumulates in hepatocytes, homocysteine rises, and neural acetylcholine pools deplete.

The prenatal brain development evidence is particularly compelling. Caudill and colleagues (2018, The FASEB Journal, PMID 29801136) conducted a randomized controlled feeding trial in 26 pregnant women during the third trimester, comparing 480 mg/day choline (slightly above the AI) to 930 mg/day. Infants born to mothers in the higher choline group showed significantly faster information processing speed at 4, 7, 10, and 13 months of age—a marker of cognitive development that predicts later IQ. The effect was dose-dependent and robust, with Cohen’s d effect sizes ranging from 0.4 to 0.7. This trial fundamentally shifted thinking about choline requirements during pregnancy; the current AI may be insufficient for optimal fetal neural development.

Observational data from large cohorts supports this picture. Boeke and colleagues (2013, American Journal of Epidemiology, PMID 23425631) analyzed 895 mother-child pairs from the Project Viva cohort, finding that children of mothers in the highest quartile of second-trimester choline intake (>449 mg/day) scored 1.4 points higher on visual memory tests at age 7 compared to the lowest quartile (<237 mg/day). While this is an observational association that cannot prove causation, the effect size is approximately one-third of a standard deviation—meaningful in educational contexts—and the finding is consistent with the RCT data. The convergence of randomized trial and cohort evidence strengthens confidence in the prenatal benefit.

Choline bitartrate is the most economical form but not the most brain-bioavailable. Unlike alpha-GPC or citicoline, choline bitartrate does not readily cross the blood-brain barrier. Much of the choline from bitartrate is oxidized in the liver or used for peripheral phospholipid synthesis. For direct cognitive enhancement, alpha-GPC or citicoline are superior. However, choline bitartrate excels at supporting systemic choline needs: liver function, methylation, and providing a substrate pool that the brain can access over time. It is the appropriate choice for general nutritional adequacy rather than acute nootropic effect. The TMAO cardiovascular concern deserves context—choline supplementation at moderate doses (under 1,000 mg) has not been shown to increase cardiovascular risk in healthy individuals.